INS and diabetes mellitus: Although each MIDY mutation alters an invariant framework residue—conserved among both vertebrate insulins and vertebrate insulin-like growth factors (23, 61, 71) —the less severe biophysical consequences of PheB24→Ser in consistent with the delayed onset of DM in patients with this mutation (4, 33).